세계의 주의력결핍 과잉행동장애(ADHD) 시장 규모 조사 : 약물 유형별, 인구 통계별, 유통 채널별, 지역별 예측(2022-2032년)

Global Attention Deficit Hyperactivity Disorder Market is valued approximately USD 14.3 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 3.70% over the forecast period 2024-2032. Attention Deficit Hyperactivity Disorder is a neurodevelopmental disorder that typically manifests in childhood and often continues into adulthood. It is characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with functioning or development. Also, new and improved medications are continually being developed. There is a shift towards long-acting stimulants and non-stimulant medications, offering more options for patients who may not respond well to traditional treatments. Non-stimulant medications, such as guanfacine and atomoxetine, are gaining popularity due to their lower risk of abuse and better side effect profiles for some patients. Thus, this trend is anticipated to support the growth of Global Attention Deficit Hyperactivity Disorder Market

Moreover, the awareness and recognition of ADHD have increased globally, leading to higher diagnosis rates. Improved diagnostic criteria and better screening processes have contributed to more individuals being identified and treated for ADHD. Also, there have been significant advancements in both pharmacological and non-pharmacological treatments for ADHD. New medications with improved efficacy and safety profiles, as well as behavioral therapies and digital therapeutics, are expanding the market. Additionally, growing public and professional awareness about ADHD, its symptoms, and its impact on quality of life is encouraging more people to seek diagnosis and treatment. Educational campaigns and advocacy by healthcare organizations and patient groups are instrumental in this regard, which anticipated to support the market growth. However, the stringent administration and governing procedures, an upsurge in medication prices, and the limited availability of non-stimulants ADHD drugs are the factors most expected to hinder the growth of the Global Attention Deficit Hyperactivity Disorder Market during the forecast period 2024-2032.

The key regions considered for the Global Attention Deficit Hyperactivity Disorder Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America was the largest regional market in terms of revenue. The attention deficit hyperactivity disorder market in North America is expanding owing to the introduction and rapid adoption of various medications. Furthermore, favourable reimbursement policies, increasing awareness of current treatment methods, improved patient affordability, and the introduction of new products are all expected to propel market expansion throughout the projection period. In September 2023, Tris Pharma, Inc. announced that Health Canada had approved the use of Quillivant ER (extended-release) to treat ADHD in children aged six to twelve years. Quillivant ER will be available in oral suspension and chewable tablet forms, marking the first time in Canada that once-daily, long-acting methylphenidate chewable and oral suspension formulations have been approved for ADHD treatment. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period.

Major market player included in this report are:

• Eli Lilly and Company
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Lupin Limited
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Mallinckrodt Inc.
• Purdue Pharma LP
• NEOS Therapeutics Inc.
• Supernus Pharmaceutical, Inc.

The detailed segments and sub-segment of the market are explained below:

By Drug Type

• Stimulants
• Non-stimulants

By Demographics

• Children
• Adults

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market

Table of Contents

Chapter 1. Global Attention Deficit Hyperactivity Disorder Market Definition and Research Assumptions

• 1.1. Research Objective
• 1.2. Market Definition
• 1.3. Research Assumptions
  • 1.3.1. Inclusion & Exclusion
  • 1.3.2. Limitations
  • 1.3.3. Supply Side Analysis
    • 1.3.3.1. Availability
    • 1.3.3.2. Infrastructure
    • 1.3.3.3. Regulatory Environment
    • 1.3.3.4. Market Competition
    • 1.3.3.5. Economic Viability (Consumer's Perspective)
  • 1.3.4. Demand Side Analysis
    • 1.3.4.1. Regulatory frameworks
    • 1.3.4.2. Technological Advancements
    • 1.3.4.3. Environmental Considerations
    • 1.3.4.4. Consumer Awareness & Acceptance
• 1.4. Estimation Methodology
• 1.5. Years Considered for the Study
• 1.6. Currency Conversion Rates

Chapter 2. Executive Summary

• 2.1. Global Attention Deficit Hyperactivity Disorder Market Size & Forecast (2022- 2032)
• 2.2. Regional Summary
• 2.3. Segmental Summary
  • 2.3.1. By Drug Type
  • 2.3.2. By Demographics
  • 2.3.3. By Distribution Channel
• 2.4. Key Trends
• 2.5. Recession Impact
• 2.6. Analyst Recommendation & Conclusion

Chapter 3. Global Attention Deficit Hyperactivity Disorder Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Challenges
• 3.3. Market Opportunities

Chapter 4. Global Attention Deficit Hyperactivity Disorder Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Attention Deficit Hyperactivity Disorder Market Size & Forecasts by Drug Type 2022-2032

• 5.1. Stimulants
• 5.2. Non-stimulants

Chapter 6. Global Attention Deficit Hyperactivity Disorder Market Size & Forecasts by Demographics 2022-2032

• 6.1. Children
• 6.2. Adults

Chapter 7. Global Attention Deficit Hyperactivity Disorder Market Size & Forecasts by Distribution Channel 2022-2032

• 7.1. Retail Pharmacy
• 7.2. Hospital Pharmacy

Chapter 8. Global Attention Deficit Hyperactivity Disorder Market Size & Forecasts by Region 2022-2032

• 8.1. North America Attention Deficit Hyperactivity Disorder Market
  • 8.1.1. U.S. Attention Deficit Hyperactivity Disorder Market
    • 8.1.1.1. Drug Type breakdown size & forecasts, 2022-2032
    • 8.1.1.2. Demographics breakdown size & forecasts, 2022-2032
    • 8.1.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
  • 8.1.2. Canada Attention Deficit Hyperactivity Disorder Market
• 8.2. Europe Attention Deficit Hyperactivity Disorder Market
  • 8.2.1. U.K. Attention Deficit Hyperactivity Disorder Market
  • 8.2.2. Germany Attention Deficit Hyperactivity Disorder Market
  • 8.2.3. France Attention Deficit Hyperactivity Disorder Market
  • 8.2.4. Spain Attention Deficit Hyperactivity Disorder Market
  • 8.2.5. Italy Attention Deficit Hyperactivity Disorder Market
  • 8.2.6. Rest of Europe Attention Deficit Hyperactivity Disorder Market
• 8.3. Asia-Pacific Attention Deficit Hyperactivity Disorder Market
  • 8.3.1. China Attention Deficit Hyperactivity Disorder Market
  • 8.3.2. India Attention Deficit Hyperactivity Disorder Market
  • 8.3.3. Japan Attention Deficit Hyperactivity Disorder Market
  • 8.3.4. Australia Attention Deficit Hyperactivity Disorder Market
  • 8.3.5. South Korea Attention Deficit Hyperactivity Disorder Market
  • 8.3.6. Rest of Asia Pacific Attention Deficit Hyperactivity Disorder Market
• 8.4. Latin America Attention Deficit Hyperactivity Disorder Market
  • 8.4.1. Brazil Attention Deficit Hyperactivity Disorder Market
  • 8.4.2. Mexico Attention Deficit Hyperactivity Disorder Market
  • 8.4.3. Rest of Latin America Attention Deficit Hyperactivity Disorder Market
• 8.5. Middle East & Africa Attention Deficit Hyperactivity Disorder Market
  • 8.5.1. Saudi Arabia Attention Deficit Hyperactivity Disorder Market
  • 8.5.2. South Africa Attention Deficit Hyperactivity Disorder Market
  • 8.5.3. Rest of Middle East & Africa Attention Deficit Hyperactivity Disorder Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Eli Lilly and Company
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Market Strategies
  • 9.3.2. Pfizer Inc.
  • 9.3.3. Johnson & Johnson Services Inc.
  • 9.3.4. Lupin Limited
  • 9.3.5. Novartis AG
  • 9.3.6. Takeda Pharmaceutical Company Limited
  • 9.3.7. Mallinckrodt Inc.
  • 9.3.8. Purdue Pharma LP
  • 9.3.9. NEOS Therapeutics Inc.
  • 9.3.10. Supernus Pharmaceutical, Inc.

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes